

## GHANA – Yellow Fever vaccine support

This decision letter sets out the programme terms of a programme.

<b>1. Country:</b> Ghana			
<b>2. Grant number:</b> 16-GHA-06b-X			
<b>3. Date of decision letter:</b> 20 January 2016			
<b>4. Date of the partnership framework agreement:</b> 11 July 2014			
<b>5. Programme title:</b> NVS, Yellow Fever Routine			
<b>6. Vaccine type:</b> Yellow Fever			
<b>7. Requested product presentation and formulation of vaccine:</b> Yellow Fever, 10 dose(s) per vial, LYOPHILISED			
<b>8. Programme duration<sup>1</sup>:</b> 2001 -2016			
<b>9. Programme budget (indicative):</b> (subject to the terms of the partnership framework agreement)			
	2001-2015	2016	Total <sup>2</sup>
Programme budget (US\$)	US\$9,359,507 <sup>3</sup>	US\$422,500	US\$9,782,007
<b>10. Vaccine introduction grant (in US\$):</b> . Not applicable			
<b>11. Indicative annual amounts:</b> (subject to the terms of the partnership framework agreement, if applicable): <sup>4</sup>			
Type of supplies to be purchased with Gavi funds in each year	2001-2015	2016	
Number of Yellow Fever vaccines doses		393,400	
Number of AD syringes		258,900	
Number of re-constitution syringes		43,300	
Number of safety boxes		3,350	
Annual amounts (US\$)	US\$9,359,507 <sup>5</sup>	US\$422,500	
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.			

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the consolidated amount for all previous years.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years.

<b>13. Self-procurement:</b> Not applicable.															
<b>14. Co-financing obligations: Reference code:</b> 16-GHA-06b-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.															
<table border="1"> <tr> <td>Type of supplies to be purchased with Country funds in each year</td> <td>2016</td> </tr> <tr> <td>Number of vaccine doses</td> <td>445,900</td> </tr> <tr> <td>Number of AD syringes</td> <td>293,500</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td>49,100</td> </tr> <tr> <td>Number of safety boxes</td> <td>3,775</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$442,465</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>US\$478,500</td> </tr> </table>	Type of supplies to be purchased with Country funds in each year	2016	Number of vaccine doses	445,900	Number of AD syringes	293,500	Number of re-constitution syringes	49,100	Number of safety boxes	3,775	Value of vaccine doses (US\$)	US\$442,465	Total co-financing payments (US\$) (including freight)	US\$478,500	
Type of supplies to be purchased with Country funds in each year	2016														
Number of vaccine doses	445,900														
Number of AD syringes	293,500														
Number of re-constitution syringes	49,100														
Number of safety boxes	3,775														
Value of vaccine doses (US\$)	US\$442,465														
Total co-financing payments (US\$) (including freight)	US\$478,500														
<b>15. Operational support for campaigns:</b> Not applicable															
<b>16. Additional reporting requirements:</b> The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.															
<table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>May 2016</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>	Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May 2016	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat									
Reports and other information	Due dates														
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May 2016														
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat														
<b>17. Financial clarifications:</b> Not applicable.															
<b>18. Other conditions:</b> There is currently a global shortage in the supply of yellow fever vaccines. The number of doses and presentation are subject to availability. Gavi will inform the Government as soon as possible of any changes in doses and/or presentation from what has been communicated to the Country.															

On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes

20 January 2016